Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov;22(11):2048-53.
doi: 10.1038/leu.2008.214. Epub 2008 Aug 28.

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

J E Castro  1 , J D Sandoval-Sus, J Bole, L Rassenti, T J Kipps
Affiliations

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

J E Castro et al. Leukemia. 2008 Nov.

Abstract

We examined the clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab. Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days). All patients were refractory to fludarabine and 86% had high-risk disease by the modified Rai classification. In all, 79% of the patients had CLL cells that expressed ZAP-70 and three patients had poor prognostic cytogenetics. The overall response rate was 93% and the complete remission rate was 36%. The median time-to-progression was 15 months and the median time-to-next treatment was 22 months. Median survival has not been reached after a median follow up of 40 months. Four patients have died of progressive disease. Patients tolerated the treatment well and serious adverse events were rare. This allowed patients to receive all planned treatments on schedule with no dose modifications. All but one patient responded to treatment and the overall survival and time-to-progression were superior to those of other published salvage regimens.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of clinical and laboratory parameters before treatment and at the end of the follow up period. (a) White blood cells count (WBC); (b) Hemoglobin values; (c) Platelet counts. (d) Lymph node area; sum of the large lymph nodes from each anatomic area; (e) Spleen size measured in centimeters below the left costal margin (BLCM). Statistical analysis was performed using paired t-test, two tailed P-values.
Figure 2
Figure 2
Survival curves for each of the indicated outcomes. The analysis was created using the product limit method of Kaplan–Meier. Median time-to-progression (TTP)-15 months. Median time-to-survival (OS) has not been reached (median follow up 40 months after treatment and 78 months after diagnosis). Median time to next treatment (TNTx) 22 months.
See this image and copyright information in PMC

References

    1. Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–4078. - PubMed
    1. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976–984. - PubMed
    1. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55:188–196. - PMC - PubMed
    1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large International Study. Blood. 2002;99:3554–3561. - PubMed
    1. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897. - PubMed

Publication types

MeSH terms